NVET Nexvet Biopharma Plc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Filing of a Complaint Concerning Whether the Sale of Nexvet Biopharma Public Limited Company to Zoetis Inc. for $6.72 Per Share is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Nexvet Biopharma Public Limited Company (NASDAQ: NVET) stock prior to April 13, 2017.

You are hereby notified that a complaint has been filed in the USDC for the Northern District of California concerning the fairness of the sale of Nexvet to a subsidiary of Zoetis Inc. for $6.72 per share in cash. To learn more about the action and your rights, go to:

http://www.zlkdocs.com/NVET-Info-Request-Form-ma-5850

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
02/06/2017

Underlying

NVETNexvet Biopharma Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nexvet Biopharma Plc

 PRESS RELEASE
Free
NVET Nexvet Biopharm...

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Nexvet Biopharma plc (Nasdaq: NVET) (“Nexvet” or the “Company”) relating to the proposed buyout of Nexvet by Zoetis Inc. Under the terms of the agreement, Nexvet shareholders are anticipated to receive $6.72 in cash for each share of Nexvet common stock held. The firm’s investigati...

June 22, 2017 1 EN
 PRESS RELEASE
Free
NVET Nexvet Biopharm...

NEXVET BIOPHARMA PLC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announc...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Nexvet Biopharma plc (NASDAQ GM: NVET)? Did you purchase any of your shares prior to April 13, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Nexvet Biopharma plc (“Nexvet” or the “Company”) (NASDAQ GM: NVET) regar...

June 20, 2017 1 EN
 PRESS RELEASE
Free
NVET Nexvet Biopharm...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Filing of a Complai...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Nexvet Biopharma Public Limited Company (NASDAQ: NVET) stock prior to April 13, 2017. You are hereby notified that a complaint has been filed in the USDC for the Northern District of California concerning the fairness of the sale of Nexvet to a subsidiary of Zoetis Inc. for $6.72 per share in cash. To learn more about the action and your rights, go to: http://w...

June 2, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch